Modified mRNA Lipid Formulations for Non-Integrating Protein Expression

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Existing methods for delivering pharmaceutical compositions, particularly modified nucleic acids like mRNA, face challenges such as integration into host cell genomic DNA, potential damage to cells, and inefficient protein expression due to multiple processing steps, especially in primary cells or modified cell lines.

Innovation Solution

The development of modified mRNA (mmRNA) compositions formulated in lipid formulations like liposomes or lipid nanoparticles, administered via various routes, which minimize immune response and enhance intracellular retention, ensuring efficient protein expression.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Productivity

If DNA is introduced into cells for protein expression, then protein production is achieved, but DNA may integrate into host cell genomic DNA causing alterations and damage

Engineering Contradiction:

Improveprotein expression efficiencyVSAvoidgenomic DNA damage

Core Design Contradiction:

ProductivityVSObject-affected harmful factors

Solution Approach 1:

The patent extracts the harmful integration step by using mRNA instead of DNA. The mRNA is delivered directly to the cytoplasm for translation, completely bypassing the nucleus and eliminating any possibility of genomic integration while still achieving protein expression.

Inventive Principle:

Principle #2Taking out (Extraction)

Solution Approach 2:

The patent introduces mRNA as an intermediary between genetic information and protein production. This intermediary approach allows protein expression without requiring DNA to enter the nucleus, thus avoiding genomic integration risks while maintaining translational capability.

Inventive Principle:

Principle #24Intermediary (Mediator)

2Productivity

If DNA is introduced into cells, then protein expression can occur, but multiple processing steps create lag times and opportunities for error

Engineering Contradiction:

Improveprotein expression rateVSAvoidlag time before functional protein generation

Core Design Contradiction:

ProductivityVSLoss of time

Solution Approach 1:

The patent extracts and eliminates the nuclear transcription step by delivering pre-transcribed mRNA directly to the cytoplasm. This removes one of the two major processing steps (transcription and translation), reducing lag time and minimizing opportunities for error while maintaining protein production capability.

Inventive Principle:

Principle #2Taking out (Extraction)

3Productivity

If DNA is introduced into primary cells or modified cell lines, then protein expression is attempted, but DNA expression is difficult to obtain at reasonable rates

Engineering Contradiction:

Improveprotein expression rateVSAvoidconsistency of DNA expression

Core Design Contradiction:

ProductivityVSReliability

Solution Approach 1:

The patent uses mRNA as a temporary, disposable genetic material that performs its function in the cytoplasm and then degrades naturally. This short-lived approach eliminates the need for stable integration or long-term maintenance of genetic material, providing reliable and consistent protein expression in primary and modified cell lines without the complications of DNA persistence.

Inventive Principle:

Principle #27Cheap short-living objects (Disposable)

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The modified mRNA compositions achieve therapeutically relevant protein levels with reduced lag times and increased efficiency, minimizing cellular damage and immune response, and are effective in various tissues and bodily fluids.

Implementation Method 1

The development of modified mRNA (mmRNA) compositions formulated in lipid formulations like liposomes or lipid nanoparticles

Methodology Applied

Scientific EffectLipid formulation encapsulation: Emulsion

Data Source

PatentUS12409226B2Delivery and formulation of engineered nucleic acids

Publication Date: 2025.09.09 MODERNATX INC

AI summary

Provided are formulations, compositions and methods for delivering biological moieties such as modified nucleic acids into cells to modulate protein expression. Such compositions and methods include the delivery of biological moieties, and are useful for production of proteins.